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Abstract
Attention has been given to the fact that overall survival of osteosarcoma has plateaued 
over the last 30 years despite the addition of chemotherapy regimens. Elucidating the 
involvement of p53 and Rb1 in osteosarcoma has not yielded many novel treatments, 
but recent studies have started to characterize how the PTEN and the PI3K pathway can 
contribute to osteosarcoma. PTEN is a tumor suppressor that regulates a variety of signal 
transduction pathways and cellular processes, mainly by antagonizing PI3K activity and 
shutting down the PI3K/Akt pathway. Loss of PTEN function with concurrent PI3K acti-
vation has been detected frequently in a multitude of cancers, including osteosarcoma. 
This chapter aims to characterize PTEN and the PI3K/Akt pathway in osteosarcoma, their 
effects on primary bone tumor behavior, and potential therapeutic targets.
Keywords: osteosarcoma, phosphatase and tensin homolog, phosphatidylinositol 
3-kinase, therapeutic applications
1. Introduction
Osteosarcoma (OS) is a malicious cancer that affects predominantly children and adolescents, 
and is the most common primary sarcoma of bone. After the advents of adjuvant multi-agent 
chemotherapy, in combination with surgery, the 5-year survival rate for OS has increased 
from 40 to 76% in children under 15 and from 56 to 66% in adolescents 15–19 years old 
[1]. Despite these advances, the prognosis for the 20% of patients that present with stage IV 
disease remains poor, and survival rates have plateaued [2]. In addition, with roughly 60% of 
cases occurring in just the second decade of life, the societal cost of OS exceeds that of many 
other cancers.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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OS also represents a unique entity among pediatric cancers, with cases arising de novo and 
already exhibiting high-grade pathology, heterogeneous karyotypes, and frequent genomic 
mutations. This genomic instability is further characterized by unusually high numbers of 
chromosomal structural variants and not single nucleotide mutations [3]. An OS genome can 
often contain over 200 of these structural variants, making it the most disordered among 
childhood cancers [4] (Figure 1).
To overcome the stagnation in survival rates, the cellular etiology and biology of OS need 
to be more completely understood. Toward this end, molecular targets that actively modu-
late essential cell processes such as cell cycle regulation, migration, mitosis, metabolism, 
and apoptosis have been studied to develop potential therapies. The most well-known and 
frustrating examples are the frequent inactivation mutations of cell cycle regulator gene 
tumor protein 53 (TP53) or tumor suppressor gene retinoblastoma protein 1 (Rb1), and 
attempts in translating these targets into applicable therapies have been met with much 
difficulty. Recent advances in cell signaling have broadly identified tyrosine kinase recep-
tors (TKRs) as prominent targets for cancer therapies, with many receptors confluencing 
on the second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3), and it is activa-
tion by phosphatidylinositol-4,5-bisphosphonate 3-kinase (PI3K). More importantly, PI3K 
and its inhibitor, phosphatase and tensin homolog (PTEN), may play significant roles in 
Figure 1. CIRCOS plots of osteosarcoma tumors. Representative CIRCOS plots of validated mutations and chromosomal 
lesions in diagnostic and metastatic osteosarcoma tumors from different patients. Loss of heterozygosity (orange), gain 
(red), and loss (blue) is shown. Intra-chromosomal (green lines) and inter-chromosomal (purple lines) translocations 
are indicated. Sequence mutations in RefSeq genes included silent single nucleotide variations (green), nonsense and 
missense single nucleotide variations (brown), splice-site mutations (dark blue), and insertion/deletion mutations (red). 
An additional track was added to the innermost ring of the plot showing the density of single nucleotide variations to 
highlight regions adjacent to structural variations characteristic of kataegis. Adapted from Figure 1A, Chen et al. [3].
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OS and represent therapeutic targets [4]. Investigations have also been centered on the 
effects of PTEN on osteoclastogenesis, and how the bone microenvironment may facilitate 
tumor expansion with PTEN loss. Therapeutic targets are expanding as strategies focus on 
restoring normal PTEN function and inhibiting PI3K pathway activation.
2. The PI3K pathway and PTEN
Class I PI3K is a family of heterodimeric signal transduction enzymes that phosphorylates the 
3′ hydroxyl group of the inositol ring on phosphatidylinositol-4,5-bisphosphate (PIP2) to PIP3. 
The implications of that biochemical mouthful are that PI3K activates one of the most influen-
tial pathways in cell cycle regulation and cell proliferation, the PI3K/Akt pathway (Figure 2).
Figure 2. PI3K/Akt signaling pathway. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.
cellsignal.com).
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The PI3K/Akt pathway was first identified when attempting to characterize insulin signal-
ing and discovering the tyrosine kinase receptor type-1 insulin-like growth factor receptor 
(IGF1R) [5]. IGFR1 is one of the many tyrosine kinase receptors (TKRs) in the cell membrane, 
in addition to G protein-coupled receptors, that can instigate signaling through the canoni-
cal PI3K pathway. Although there are three classes of PI3Ks, class I is the most involved in 
oncogenesis and divided into class IA (PI3K alpha, PI3K beta, and PI3K delta) and class IB 
(PI3K gamma) [6]. All class I PI3Ks form a heterodimer consisting of a catalytic and regulatory 
subunit. The catalytic subunits forming class IA PI3Ks are p110 alpha, beta, and delta, and 
encodedby the genes PIK3CA, PIK3CB, and PIK3CD, respectively. The regulatory subunits 
for class IA PI3Ks are p85 alpha, p85 beta, and p55 gamma encoded by PIK3R1, PIK3R2, and 
PIK3R3, respectively [7]. Class IB PI3K is formed exclusively from the catalytic subunit p110 
gamma (encoded by PIK3CG) and and the regulatory subunit p101 (encoded by PIK3R5). 
Class IA PI3Ks can be activated by TKRs including IGFR1, platelet-derived growth factor 
(PDGF), and epidermal growth factor receptor (EGFR). Class IB PI3Ks are activated only by 
G protein-coupled receptors.
Once activated, PI3K converts PIP2 to PIP3 [8]. PIP3 acts as a second messenger by recruit-
ing and activating proteins containing a pleckstrin homology domain to the plasma mem-
brane, notably the phosphoinositide-dependent kinase 1 (PDK1) and serine-threonine 
kinase Akt (also known as protein kinase B) [9]. Akt is activated via two phosphorylation 
sites, and the first occurs at threonine 308 by none other than PDK1. The second phos-
phorylation required for Akt activation occurs at serine 473 by a number of kinases includ-
ing PDK1 or even Akt itself [7]. Once activated, Akt translocates to the cell cytoplasm or 
nucleus to set in motion a number of downstream effects to inhibit apoptosis and induce 
protein synthesis.
One of the most important downstream targets of Akt is mammalian target of rapamycin 
(mTOR), a 289 kDa serine/threonine kinase that drives one of the two complexes in mamma-
lian cells, mTORC1 or mTORC2. mTORC1 has been implicated as a driver of many cancers, 
and mTORC2 can create a positive feedback loop by phosphorylating and activating Akt at 
serine 473 [10]. mTOR is activated when Akt phosphorylates and inactivates a regulatory pro-
tein in the mTORC1 complex called proline-rich Akt substrate of 40 kDa (PRAS40). Akt also 
inhibits the tumor suppressor protein tuberous sclerosis protein 2 (TSC2) which can result in 
activation of mTOR [11]. The activation of mTORC1 promotes protein synthesis and cellular 
proliferation by phosphorylation of eukaryotic translation initiation factor 4E-binding protein 
1 (4EBP1) and ribosomal protein S6 kinase polypeptide 1 (S6K1) which in turn phosphorylates 
ribosomal protein S6 (RPS6). The majority of mTOR inhibitors (including rapamycin deriva-
tives) function by inhibiting mTORC1.
In addition to mTOR, important downstream targets of the PI3K/Akt pathway include pro-
motion of cyclin-dependent kinase 4 (CDK4) to support cell cycle progression [12] and acti-
vation of nuclear factor-kappa B (NF-κB) which initiates transcription of many target genes 
including those seen in drug-resistant malignancies [13]. Akt also inhibits Bcl-2-associated 
death promoter (BAD), caspase-9, and forkhead box O3 (FOXO3), while activating cyclic AMP 
response element-binding protein (CREB), all of which serve to prevent apoptosis [14–16].
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The grandiosity and arborous nature of the of the PI3K/Akt pathway emphasize the current 
attention being given to phosphatase and tensin homolog (PTEN) (Figure 3), a lipid phos-
phatase that directly antagonizes PI3K during the initiation steps of the PI3K/Akt pathway 
[17]. PTEN is a 200 kb gene located on chromosome 10q23.3 [18], which encodes a 60-kDa 
dual-specificity phosphatase that cleaves phosphate groups from phospholipids (including 
phosphatidylinositols) as well as proteins (serine, threonine, and tyrosine residues including 
those on TKRs) [19]. PTEN functions as a tumor suppressor by dephosphorylating and inacti-
vating the second messenger PIP3 to PIP2, cogently shutting down the PI3K/Akt pathway and 
promoting cell cycle regulation and apoptosis [20]. The function of PTEN is further supported 
by phosphorylation at tyrosine 336 by RAK, which prevents ubiquitin-mediated proteosomal 
degradation [21]. PTEN also has tumor suppressor functions outside of the canonical PI3K 
pathway and regulates a variety of cellular processes and signal transduction pathways, such 
as controlling cell proliferation through cyclin D1 levels [22, 23]. A 576 amino acid transla-
tional variant of PTEN has been discovered, termed PTEN long, that can be secreted and enter 
other cells, enabling tumor suppressor effects in a paracrine-like manner [24]. The C-terminus 
of PTEN is thought to be essential in maintaining heterochromatin structure and genomic 
stability [25].
3. Relevance of PTEN and PI3K to cancer processes
OS is already prone for structural genomic variations and chromothripsis, and whether this is 
due to selective loss of the TP53 gene or an intrinsic feature of OS itself is beyond the scope of 
this paper. What this intrinsic genomic instability does allow for is the selection of cancer cells 
that consistently develop predictable mutations that are beneficial for tumor survival [3]. This 
Figure 3. A ribbon diagram of the PTEN tumor suppressor. The phosphatase domain and the C2 domains are shown in 
yellow and green ribbons, respectively. Reproduced from Das et al. [98].
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phenomenon of localized hypermutation in a cancer genome is called kataegis. Two of these 
predictable mutations in OS are the frequent loss of PTEN and activation of the PI3K/Akt 
pathway [26, 27]. The PI3K/Akt pathway is activated in a multitude of cancers, as its overall 
effects are to promote cellular proliferation and survival while reducing apoptosis. Akt upreg-
ulates expression of murine double minute 2 (MDM2) which further inhibits release of tumor 
protein 53 (p53) [28] and can result in very aggressive phenotypes since p53 is already stunted 
in many OS cancers. p53 itself has been shown to be a potent dual inhibitor of mTORC1 and 
mTORC2 in OS cells, further supporting a highly active PI3K/Akt pathway in OS tumors [29].
Loss of PTEN function has been detected frequently in many different forms of cancer 
including breast, prostate, lung, gastric, colon, and skin cancer, as well as endometrial 
carcinoma. The frequency of mono-allelic mutations of the PTEN locus is estimated to 
be 50–80% in sporadic tumors, with complete loss generally associated with advanced 
malignancies and metastases [30]. In fact, the PTEN protein was initially referred to as 
MMAC1 for “mutated in multiple advanced cancers” [18]. PTEN deletion mutations were 
first identified in canine OS cell lines [31], and retrospectively, it is interesting to note that 
chromosomal loss of 10q has been a frequent occurrence in over 50% of human OS tumor 
samples analyzed in some studies [32]. Specific mutations in PTEN have been identified in 
44% of pediatric OS [3].
The genetic disruption of PTEN often leads to unchecked PI3K/Akt signaling [33]. In breast 
cancer cell lines, a functional PTEN can directly inhibit cell growth [21]. More recently, the 
PI3K/Akt pathway and PTEN have risen to the forefront of OS research since the surprise 
finding by Perry et al. that identified biologically and clinically relevant alterations in the 
PI3K/Akt pathway in 24% of OS samples [4]. Furthermore, when comparing the same OS 
tumors to a murine model of OS (with conditional deletions of TP53 and Rb1 in the preosteo-
blast), both contained somatic mutations in PTEN and PIK3R1.
4. How is PTEN lost in cancer?
There are numerous methods by which the PI3K/Akt pathway is activated in malignancies, 
often the consequence of upregulation via a multitude of TKRs and G-protein-coupled recep-
tors. With PTEN having a pronounced effect on the PI3K/Akt pathway, PTEN function is 
accordingly inhibited in many ways. Recurrent PTEN germline mutations often involve exon 
5, which codes for its phosphatase domain, and missense and nonsense somatic mutations 
also can occur in exons 5–8 [34]. Cowden’s disease (also known as multiple hamartoma syn-
drome) is an autosomal dominant condition with increased risk of thyroid, breast, uterine, 
and kidney cancers that results from similar somatic inactivating mutations of PTEN [35]. The 
end result is a functional loss of heterozygosity, which is sufficient to produce oncogenesis, 
as PTEN is essential for embryonic development, and homozygous loss results in embryonic 
lethal phenotype in mice [36].
At the epigenetic level, PTEN is inhibited by aberrant promoter hypermethylation of CpG 
islands, which is a poor prognostic indicator in numerous cancer types including breast, 
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colorectal, uterine, and malignant melanoma [37–40]. While hypermethylation has been 
identified in several soft tissue sarcomas and in murine models of OS, it has only been 
studied in human OS tumors in vitro [41]. PTEN protein translation can be negatively regu-
lated by many microRNAs including miR-92a, miR-17, miR-128, and miR-130/131 [42–44]. 
Theoretically, structural features of PTEN itself could prove to be potential sites for compro-
mising protein stability. Post-translational modification such as phosphorylation at tyrosine 
336 could be abrogated, thus promoting protein degradation. Protein localization to the cell 
membrane or nucleus could be affected if the C2 or PDZ-binding domains of PTEN were 
impaired. Although the majority of inactivating mutations affect the phosphatase domain of 
PTEN, preventing it from cleaving PIP3 to PIP2, there are several ways that PTEN expression 
and dysregulation can be imparted in malignancies.
5. PTEN in bone and osteosarcoma
PTEN is frequently deactivated through deletions in human OS tumor samples [26]. A sleep-
ing beauty forward genetic screen by Moriarity et al. supports the role of PTEN loss as a 
key driver in osteosarcomagenesis in mice, with a concordant enrichment of genes involved 
in the PI3K/Akt pathway [45]. The PI3K/Akt pathway is already recognized as a common 
effector for RTK-activating mutations in cancer [46]. The loss of PTEN only further promotes 
this, but what factors in the bone microenvironment that facilitate tumor expansion in the 
absence of PTEN is unknown. It would be very un-Darwinian for OS, multiple myeloma, and 
bone metastases to all have PTEN derangements for unrelated reasons. The effects of PTEN 
on osteoclastogenesis and receptor activator of nuclear factor-kappa-B ligand (RANKL) may 
be the commonality among these cancers.
There is a vicious cycle that begins when a malignancy metastasizes or originates in bone that 
allows it to propagate and induce osteolysis. Metastatic tumor cells can secrete interleukin-1 
(IL-1) and parathyroid hormone-related protein (PTHrP), which stimulate RANKL produc-
tion and secretion from osteoblasts. IL-1 also stimulates osteoblasts to secrete IL-6 via the 
PI3K/Akt pathway, and IL-6 is a potent stimulator of osteoclastogenesis [47]. OS cells also 
directly produce RANKL. RANKL binding to the RANK receptor on osteoclast precursors 
activates osteoclast differentiation and osteolysis. The increased bone resorption results in the 
release of bone morphogenetic proteins (BMPs) and insulin-like growth factor 1 (IGF-1) that 
further attract and stimulate the growth of cancer cells in bone, thus initiating a vicious cycle 
of tumor expansion and osteolysis [48, 49].
PI3K/Akt acts as a cog in the wheel of this vicious cycle, being activated by RANKL and 
resulting in downstream expression of NFATc1, a key transcription factor of osteoclastogen-
esis [50]. This gives PTEN the opportunity to prevent bone resorption by inhibiting the PI3K/
Akt pathway, thus suppressing RANKL-induced osteoclast differentiation and stopping the 
vicious cycle [51]. This would support the loss of PTEN in aggressive bony malignancies, 
preventing stimulation of osteoblasts by IL-1 and osteoclasts by RANKL. Murine models with 
PTEN deletions have shown increased osteoblast proliferation and bone mass [52], in addi-
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tion to increased osteoclast differentiation [53]. Fibroblast growth factor 18 (FGF18) is another 
stimulator of bone growth, and with all FGF receptors being RTK’s, its effects are mediated 
via the PI3K/Akt pathway and can be inhibited by PTEN [54]. Vascular endothelial growth 
factor (VEGF) and EGFR are both upregulated in OS and are key activators of the PI3K/Akt 
pathway [26, 55].
The finding that WNT5A may phosphorylate Akt is further support for the bone microenvi-
ronment being conducive to tumor growth [56]. WNT5A is expressed on osteoblast-precursor 
cells and activates RTK-like orphan receptors (Ror) on osteoclast precursors, culminating in 
increased expression of RANK on osteoclasts and enhancing RANKL osteoclastogenesis [57]. 
The result of PTEN loss in OS would be twofold in promoting the effects of WNT5A: (1) 
further increasing RANKL production by osteoblasts and (2) enabling WNT5A-related Akt 
activation, both increasing osteoclastogenesis and osteolysis.
6. PTEN in osteosarcoma and metastasis
WNT5A also provides segue into the realm of OS metastases. Metastatic melanoma cell motility 
and invasiveness are increased through WNT5A and Akt. Akt is increased in metastatic OS speci-
mens, and inhibiting Akt in mice decreases pulmonary metastases [7]. WNT5A is even implicated 
in helping to initiate the epithelial to mesenchymal transition (EMT), a key event in malignant 
cancers developing metastatic potential [58, 59]. The effect of PTEN loss in promoting EMT has 
been shown in prostate, colorectal, and OS cancer cells [60–62]; however, the role of EMT in mes-
enchymal tumors including OS is still a topic of debate and a focus of current research.
IL-6 is also increased in OS tissues and can promote ICAM-1 expression and cell motility 
in OS in vitro, possibly correlating to metastatic potential. These effects of IL-6 in OS can be 
negated by Akt inhibition [63], suggesting that PTEN could also negate this effect in bone by 
preventing IL-1 from stimulating IL-6 through PI3K/Akt. Another promoter of metastasis is 
the chemokine CXCL12 and its receptor CXCR4, both induced by IL-1 and strongly linked to 
bone metastasis [64]. PTEN is involved in the negative regulation of CXCR4, and in prostate 
cancer, PTEN loss induces CXCL12/CXCR4 expression [65].
Focal adhesion kinase (FAK) deserves special recognition as a direct target of PTEN outside 
of the canonical PI3K pathway, as it is a target of the protein phosphatase (not lipophos-
phatase) domain of PTEN [66]. Activation of FAK by phosphorylation (pFAK) promotes 
proliferation and invasion of tumor cells and increases matrix metalloproteinases that can 
degrade the extracellular matrix. FAK and pFAK are overexpressed in human OS samples 
and independently predict overall and metastasis-free survival [67]. This effect may be 
reversed in OS cells with PTEN transfections, which exhibit decreased migration and adhe-
sion capabilities and concomitant downregulation of pFAK and MMP-9, further supporting 
the loss of PTEN in OS [68]. Just as FAK can be prognostic in human OS, the presence of 
PTEN in tumor resections is significantly associated with improved survival prognosis [69]. 
Unfortunately neither can be correlated with response to current chemotherapy regimens.
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7. Therapeutic applications targeting PI3K/Akt pathway and PTEN in 
osteosarcoma
There is an abundance of convincing evidence supporting a key role for PTEN in OS, but 
from a therapeutic standpoint, this assumes that there is causality and not just correlation 
between PTEN loss and poor patient prognosis. Two major therapeutic strategies are restor-
ing normal PTEN function and inhibiting the PI3K pathway. Comparing these two strategies 
could also aid in distinguishing how PTEN serves as a tumor suppressor beyond the canoni-
cal PI3K pathway.
Many chemotherapy agents already target various levels of the PI3K/Akt pathway, and 
several are in various phases of clinical trials involving OS. These include small molecule 
inhibitors of PI3K, Akt, and numerous mTOR inhibitors (Table 1). Countless PI3K small 
molecule inhibitors have been developed, but several have specifically been effective in 
OS including GSK458, LY294002, BYL719, and BKM120 (Buparlisib) [4, 70–72]. Pictilisib 
(GDC-0941) is a pan PI3K inhibitor that has entered phase I clinical trials for advanced 
solid tumors [73]. Aminopeptidase N (also known as CD13) is a surface receptor activated 
by IL-6 that can stimulate PI3K and is involved in tumor invasion. An aminopeptidase N 
inhibitor, ubenimex, is currently used for acute myeloid leukemia treatments and may help 
prevent OS metastases [74]. The Akt inhibitors perifosine and MK-2206 both exert anti-OS 
activity in vitro [75, 76]. Inhibitors of the mTOR complex are the most numerous of this 
pathway, being extensively studied and developed since the discovery of the mTORC1 
inhibitor rapamycin in 1975. Many new inhibitors of the mTORC1/2 complex are currently 
being developed, but several in particular have been tested on OS either in vivo or are 
in various phases of clinical trials: temsirolimus [77], ridaforolimus [78], everolimus [79], 
XL388 [80], and NVP-BEZ235 [81]. Apitolisib (GDC-0980) has entered phase I clinical trials 
for patients with advanced solid tumors and could precede future studies involving OS 
patients [82].
With current chemotherapy regimens for OS having reached seemingly maximum effi-
cacy, attention has been generous in identifying new agents to increase PTEN function 
in OS. MicroRNA-21 (miR-21) is one of the first mammalian microRNA’s discovered that 
happens to be highly expressed in bone marrow and post-transcriptionally regulates 
a number of tumor suppressors including PTEN. miR-21 is overexpressed, suppresses 
PTEN in OS, and has been identified as a potential therapeutic target [83]. MicroRNAs are 
small non-coding pieces of RNA, similar to small interfering RNA (siRNAs) that bind to 
complimentary pieces of messenger RNA, effectively preventing translation of the mRNA 
into proteins. In multiple myeloma, miR-21 inhibitors have been used in vivo using 
murine models to cause tumor suppression, with tumors exhibiting increased PTEN 
and decreased p-Akt levels [84]. Targeting microRNAs could show promise, as numer-
ous microRNAs are specifically upregulated in OS cell lines [44]. In addition to miR-21, 
miR-17 and miR-221 are also increased and can inhibit PTEN in OS cells and tissues, 
potentially being therapeutic targets [42, 85]. Further incentive for therapeutic inhibition 
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of miR-221 is its association with cisplatin resistance, an agent frequently included in 
chemotherapy regimens for OS.
Targeted molecular therapy using RTK inhibitors has been fruitful in many cancers. EGFR 
causes activation of Akt in OS, and resistance to EGFR inhibitors can be seen in tumors with 
PTEN deletions leading to unchecked Akt activity. This is encouraging for possible combi-
nation therapies that restore PTEN function and inhibit either the PI3K pathway or RTKs. 
One RTK inhibitor in particular, sorafenib, may have interactions with PTEN. Sorafenib is 
a small molecule inhibitor of many RTKs including platelet-derived growth factor receptors 
(PDGFR), VEGF, EGFR, and Raf family kinases and is currently used in advanced renal cell 
carcinoma, thyroid cancer, and hepatocellular carcinoma. In thyroid cancers in vivo, sorafenib 
reversed tumor growth that had been attributed to PTEN loss [86]. Interactions between 
sorafenib and PTEN can also explain why acquired resistance to sorafenib in hepatocellular 
Agent Target Therapies
GSK458 PI3K Phase I trial for advanced solid tumors
LY294002 PI3K Efficacy against OS cells in vitro
BYL719 (Alpelisib) PI3K alpha Phase I for advanced solid tumors
BKM120 (Buparlisib) PI3K Phase Ib for advanced solid tumors
GDC0941 (Pictilisib) PI3K Phase I for advanced solid tumors
Bestatin (Ubenimex) Aminopeptidase N Efficacy against OS cells in vitro
KRX0401 (Perifosine) PI3K, Akt Efficacy against OS cells in vitro
MK-2206 Akt Phase I for advanced solid tumors and 
metastatic breast cancer
Rapamycin (Sirolimus) mTORC1 Phase II for soft tissue sarcoma and 
osteosarcoma
CCI779 (Temsirolimus) mTORC1 Phase II for soft tissue sarcoma and recurrent/
refractory sarcoma
MK8669 (Ridaforolimus) mTORC1 Phase II and III for advanced soft tissue 
sarcoma and osteosarcoma
RAD001 (Everolimus) mTORC1 Phase II for advanced osteosarcoma
XL388 mTORC1/2 Efficacy against OS cells in vitro
NVP-BEZ235 (Dactolisib) PI3K, mTORC1/2 Phase I for advanced solid tumors
Efficacy in vivo against OS in mice
GDC0980 (Apitolisib) PI3K, mTORC1/2 Phase I for advanced solid tumors
Sorafenib RTK Phase II for advanced osteosarcoma
“Advanced” denotes tumors that have metastasized, recurred, failed prior chemotherapies, or are not surgically 
resectable.
Table 1. Current agents targeting PI3K/Akt pathway with potential against osteosarcoma.
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carcinomas is partly due to miR-21-mediated inhibition of PTEN [87]. Notably, sorafenib is the 
first targeted chemotherapy agent used for treatment of OS. Sorafenib did demonstrate some 
activity as a single agent in patients with unresectable OS, with median progression free and 
overall survival of 4 and 7 months, respectively [88]. Additional effect was seen with combina-
tion of sorafenib and the mTOR inhibitor everolimus [78], and further improvement could be 
achieved with combination therapy specifically targeting PTEN or miR-21.
Demethylating agents may be able to restore PTEN function by removing hypermethylated pro-
moter regions in cancer cells. In many cancerous processes, methyl groups are added through-
out the genome preferentially in the promoter regions of tumor suppressor genes, to the five 
position of cytosine of a CpG dinucleotide (i.e., where a guanine is preceded by a cytosine). 
These 5-methylcytosines act as roadblocks on a cell’s DNA, preventing transcription of tumor 
suppressor genes. Although hypermethylation occurs in many cancers, it is difficult to show 
that this occurs in OS in vivo. 5-Azacytidine is a commonly used demethylating agent approved 
for treatment of myelodysplastic syndrome. It has been shown in human OS in vitro that the 
PTEN gene promoter is hypermethylated and that 5-azacytidine treatments activate PTEN 
expression [89]. Initial uses of 5-azacytidine as an isolated agent in OS were disappointing [90]; 
however, recent investigations show a role for combination therapies targeting PTEN through 
epigenetic regulation [91].
Many other specific activators of PTEN have been recently identified, but at this time, they 
remain tested only in vitro. Tepoxalin, a 5-lipogenase inhibitor, appears to increase PTEN 
activity by preventing its alkylation or oxidation in canine OS cell lines [92]. Evodiamine, 
derived from the fruit of the Evodia rutaecarpa plant, inhibits human OS cell proliferation 
by increasing both protein and gene levels of PTEN [93]. Celecoxib, a cyclooxygenase-2 
inhibitor, inhibits hepatocarcinoma tumor growth and angiogenesis in mice by concur-
rently increasing PTEN and decreasing PI3K levels [94]. Similarly, using a VEGF inhibitor 
in combination with celecoxib may prove beneficial in human OS [95]. Even caffeine has 
been shown to induce PTEN activation and many other tumor suppressor genes, while 
decreasing expression of IL-6 and matrix metallopeptidase 2 [96, 97]. Overall there is much 
promise for improving OS treatments by honing our understanding of PTEN and the PI3K 
pathway (Table 2).
Agent Target Effect on PTEN
None yet available miR17, miR21, miR221 Reduced inhibition of PTEN by miR
5-Azacytidine Demethylating agent Increases PTEN in human OS cells
Tepoxalin 5-Lipogenase inhibitor Increases PTEN in canine OS cells
Evodiamine Unknown Increases PTEN in human OS cells
Celecoxib Cyclooxygenase-2 inhibitor Increases PTEN and decreases PI3K 
in vitro
Caffeine Unknown Activates PTEN, decreases expression 
of IL-6 and MMP2
Table 2. Potential future agents for targeting PTEN in osteosarcoma.
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8. Conclusion
The stagnation of current chemotherapy regimens has forced us to look beyond the usual 
players in oncogenesis. The mentality behind the recent targeted developments against OS 
involving PI3K and PTEN could be expanded to benefit many tumor types. We have been 
able to see through the genetic chaos of OS, finding predictability in the form of kataegis and 
the seemingly random mutations that converge on the PI3K/Akt pathway. Significant inroads 
still need to be made to clinically validate what has been proven on the bench and in animal 
models, but sarcomatologists are optimistic that potential therapies and improved patient 
survival lie within the PI3K and PTEN axis.
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